Northwest Biotherapeutic, a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced commencement of production of its first dendritic cell Cancer Vaccine for a compassionate use patient at its recently licensed production facility in Sawston, UK. This milestone follows approval by the UK Medicines and Healthcare Products Regulatory Agency (MHRA) of a […]

The post Northwest Biotherapeutics Announces Commencement Of Cancer Vaccine Production At Its Sawston, UK Facility first appeared on World Pharma Today.